<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39344023</PMID><DateRevised><Year>2024</Year><Month>09</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1365-2362</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Sep</Month><Day>29</Day></PubDate></JournalIssue><Title>European journal of clinical investigation</Title><ISOAbbreviation>Eur J Clin Invest</ISOAbbreviation></Journal><ArticleTitle>Lung damage in SARS-CoV-2 patients: An autopsy study in the era of vaccination.</ArticleTitle><Pagination><StartPage>e14325</StartPage><MedlinePgn>e14325</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/eci.14325</ELocationID><Abstract><AbstractText Label="AIMS" NlmCategory="OBJECTIVE">The contribution of SARS-CoV-2 infection on lung damage and the effect of vaccination on either containing the number of deaths or mitigating lung damage has not been systematically investigated.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Post-mortem analysis was performed among consecutive in-patients with COVID-19 deceased in the Province of Trieste (2020-2022). The outcomes of the study were (i) rates of in-hospital mortality, (ii) contribution of COVID-19 to death, (iii) histological extent of lung injury and (iv) impact of vaccination.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 1038 consecutive hospitalized patients who died with SARS-CoV-2 infection were autopsied and deep histological analysis of the lungs was performed in a randomly selected sample of 508 cases. Among them, SARS-CoV-2 infection was (a) the cause of death (n = 90), (b) contributing to death (n = 304) and (c) an accompanying feature (n = 114). The incidence of SARS-CoV-2 infection as the primary cause of mortality decreased over time (23.8% in 2020, 20.9% in 2021 and 7.9% in 2022). On multivariable analysis, vaccination (any dose) was independently associated with lower rates of death related to SARS-CoV-2 infection (HR .15, p &lt; .001), after adjusting for other independent predictors. A total of 172 patients were vaccinated at least with two doses at the time of death: 93% triple-vaccinated, 7% double-vaccinated. On histological analysis, vaccinated patients had a greater frequency of pneumonia severity score 0 and 1 (20.3% vs. 5.4% and 20.9% vs. 7.7%, p &lt; .001, respectively), and a substantially lower proportion of pneumonia severity score 3 (26.2% vs. 55.1%, p &lt; .001) compared to unvaccinated patients.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">COVID-19 vaccination has substantially reduced rates of death related to SARS-CoV-2 infection over time and may have the ability to mitigate lung damage.</AbstractText><CopyrightInformation>© 2024 The Author(s). European Journal of Clinical Investigation published by John Wiley &amp; Sons Ltd on behalf of Stichting European Society for Clinical Investigation Journal Foundation.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bussani</LastName><ForeName>Rossana</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Institute of Pathological Anatomy and Histology, Azienda Sanitaria Universitaria Giuliano-Isontina, University of Trieste, Trieste, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical, Surgical and Health Sciences, University of Trieste, Trieste, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Porcari</LastName><ForeName>Aldostefano</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-3307-0825</Identifier><AffiliationInfo><Affiliation>Center for Diagnosis and Treatment of Cardiomyopathies, Cardiovascular Department, Azienda Sanitaria Universitaria Giuliano-Isontina (ASUGI), University of Trieste, Trieste, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>European Reference Network for Rare, Low Prevalence and Complex Diseases of the Heart-ERN GUARD-Heart, Trieste, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pinamonti</LastName><ForeName>Maurizio</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute of Pathological Anatomy and Histology, Azienda Sanitaria Universitaria Giuliano-Isontina, University of Trieste, Trieste, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iacobucci</LastName><ForeName>Anthea</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Medical, Surgical and Health Sciences, University of Trieste, Trieste, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Belladonna</LastName><ForeName>Eleonora</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Medical, Surgical and Health Sciences, University of Trieste, Trieste, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tomasini</LastName><ForeName>Ariella</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Medical, Surgical and Health Sciences, University of Trieste, Trieste, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zanconati</LastName><ForeName>Fabrizio</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Institute of Pathological Anatomy and Histology, Azienda Sanitaria Universitaria Giuliano-Isontina, University of Trieste, Trieste, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical, Surgical and Health Sciences, University of Trieste, Trieste, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Collesi</LastName><ForeName>Chiara</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Medical, Surgical and Health Sciences, University of Trieste, Trieste, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>International Centre for Genetic Engineering and Biotechnology (ICGEB), Trieste, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Giacca</LastName><ForeName>Mauro</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Medical, Surgical and Health Sciences, University of Trieste, Trieste, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>International Centre for Genetic Engineering and Biotechnology (ICGEB), Trieste, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Cardiovascular Medicine &amp; Sciences, King's College London, British Heart Foundation Centre of Research Excellence, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Berlot</LastName><ForeName>Giorgio</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Medical, Surgical and Health Sciences, University of Trieste, Trieste, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sinagra</LastName><ForeName>Gianfranco</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Medical, Surgical and Health Sciences, University of Trieste, Trieste, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Diagnosis and Treatment of Cardiomyopathies, Cardiovascular Department, Azienda Sanitaria Universitaria Giuliano-Isontina (ASUGI), University of Trieste, Trieste, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>European Reference Network for Rare, Low Prevalence and Complex Diseases of the Heart-ERN GUARD-Heart, Trieste, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Silvestri</LastName><ForeName>Furio</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Institute of Pathological Anatomy and Histology, Azienda Sanitaria Universitaria Giuliano-Isontina, University of Trieste, Trieste, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Eur J Clin Invest</MedlineTA><NlmUniqueID>0245331</NlmUniqueID><ISSNLinking>0014-2972</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID‐19</Keyword><Keyword MajorTopicYN="N">SARS‐CoV‐2</Keyword><Keyword MajorTopicYN="N">mortality</Keyword><Keyword MajorTopicYN="N">post‐mortem analysis</Keyword><Keyword MajorTopicYN="N">vaccination</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>7</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>30</Day><Hour>10</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>30</Day><Hour>10</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>30</Day><Hour>0</Hour><Minute>23</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39344023</ArticleId><ArticleId IdType="doi">10.1111/eci.14325</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Russell CD, Lone NI, Baillie JK. Comorbidities, multimorbidity and COVID‐19. Nat Med. 2023;29(2):334‐343.</Citation></Reference><Reference><Citation>Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID‐19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020;323(13):1239‐1242.</Citation></Reference><Reference><Citation>Ackermann M, Verleden SE, Kuehnel M, et al. Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid‐19. N Engl J Med. 2020;383(2):120‐128.</Citation></Reference><Reference><Citation>Liu J, Li Y, Liu Q, et al. SARS‐CoV‐2 cell tropism and multiorgan infection. Cell Discov. 2021;7:17.</Citation></Reference><Reference><Citation>Liu F, Han K, Blair R, et al. SARS‐CoV‐2 infects endothelial cells in vivo and in vitro. Front Cell Infect Microbiol. 2021;11:701278.</Citation></Reference><Reference><Citation>Bozio CH, Butterfield KA, Briggs Hagen M, et al. Protection from COVID‐19 mRNA vaccination and prior SARS‐CoV‐2 infection against COVID‐19‐associated encounters in adults during delta and omicron predominance. J Infect Dis. 2023;227(12):1348‐1363.</Citation></Reference><Reference><Citation>Barda N, Dagan N, Ben‐Shlomo Y, et al. Safety of the BNT162b2 mRNA Covid‐19 vaccine in a Nationwide setting. N Engl J Med. 2021;385(12):1078‐1090.</Citation></Reference><Reference><Citation>Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid‐19 vaccine. N Engl J Med. 2020;383(27):2603‐2615.</Citation></Reference><Reference><Citation>Sinagra G, Merlo M, Porcari A. Exploring the possible link between myocarditis and mRNA COVID‐19 vaccines. Eur J Intern Med. 2021;92:28‐30.</Citation></Reference><Reference><Citation>Ssentongo P, Ssentongo AE, Voleti N, et al. SARS‐CoV‐2 vaccine effectiveness against infection, symptomatic and severe COVID‐19: a systematic review and meta‐analysis. BMC Infect Dis. 2022;22(1):439.</Citation></Reference><Reference><Citation>Bussani R, Schneider E, Zentilin L, et al. Persistence of viral RNA, pneumocyte syncytia and thrombosis are hallmarks of advanced COVID‐19 pathology. EBioMedicine. 2020;61:103104.</Citation></Reference><Reference><Citation>Dal Ferro M, Bussani R, Paldino A, et al. SARS‐CoV‐2, myocardial injury and inflammation: insights from a large clinical and autopsy study. Clin Res Cardiol. 2021;110(11):1822‐1831.</Citation></Reference><Reference><Citation>Bussani R, Zentilin L, Correa R, et al. Persistent SARS‐CoV‐2 infection in patients seemingly recovered from COVID‐19. J Pathol. 2023;259(3):254‐263.</Citation></Reference><Reference><Citation>Nab L, Parker EPK, Andrews CD, et al. Changes in COVID‐19‐related mortality across key demographic and clinical subgroups in England from 2020 to 2022: a retrospective cohort study using the OpenSAFELY platform. Lancet Public Health. 2023;8(5):e364‐e377.</Citation></Reference><Reference><Citation>Meslé MMI, Brown J, Mook P, et al. Estimated number of lives directly saved by COVID‐19 vaccination programs in the WHO European region, December 2020 to march 2023. medRxiv. 2024;12(9):714‐727.</Citation></Reference><Reference><Citation>HDR UK COALESCE Consortium. Undervaccination and severe COVID‐19 outcomes: meta‐analysis of national cohort studies in England, Northern Ireland, Scotland, and Wales. Lancet (London, England). 2024;403:554‐566.</Citation></Reference><Reference><Citation>Colombo D, Del Nonno F, Marchioni L, et al. Autopsies revealed pathological features of COVID‐19 in unvaccinated vs vaccinated patients. Biomedicine. 2023;11(2):551.</Citation></Reference><Reference><Citation>Schwab C, Merle U, Schirmacher P, Longerich T. Lethality of SARS‐CoV‐2 infection‐a comparative autopsy study focusing on COVID‐19 development and virus variants. Histopathology. 2023;83(2):242‐251.</Citation></Reference><Reference><Citation>Le Rutte EA, Shattock AJ, Marcelino I, Goldenberg S, Penny MA. Efficacy thresholds and target populations for antiviral COVID‐19 treatments to save lives and costs: a modelling study. eClinicalMedicine. 2024;73:102683.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle>